Hal Hirte
Corporate Officer/Principal chez Alethia Biotherapeutics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Yves Cornellier | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | 22 ans |
Mario Filion | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | 22 ans |
Gilles Bernard Tremblay | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | 24 ans |
Elizabeth Douville | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | - |
Ela Borenstein | F | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | - |
Jacques Jolivet | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | - |
Janique Forget | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | - |
Julie Laurin | M | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations